Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Group 1 - Oncocyte Corp. will participate in BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah on February 11-12, 2025 [1][2] - The company will host one-on-one meetings with interested investors during the conference [1] - Oncocyte is recognized for its innovative diagnostics technology, including tests like VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ [2] Group 2 - VitaGraft™ is a clinical blood-based test for solid organ transplantation monitoring [2] - GraftAssure™ is a research use only (RUO) blood-based test for solid organ transplantation monitoring [2] - DetermaIO™ assesses the tumor microenvironment to predict response to immunotherapies, while DetermaCNI™ monitors therapeutic efficacy in cancer patients [2]